Nucleome Therapeutics utilizes advanced genomic decoding techniques to analyze regulatory elements within the human genome, enabling the identification of novel therapeutic targets for precision medicine. This approach addresses the challenge of developing effective treatments for complex diseases by enhancing the scale and accuracy of genetics-led drug discovery.
Funding
$42M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of effective treatments for complex diseases is hindered by the challenge of accurately identifying and targeting the regulatory elements within the human genome that control gene expression. Current genetics-led drug discovery methods often lack the scale and precision needed to fully understand and exploit these regulatory mechanisms.
Solution
Nucleome Therapeutics employs advanced genomic decoding techniques to analyze the regulatory elements of the human genome, thereby enhancing the identification of novel therapeutic targets for precision medicine. By increasing the scale, precision, and capability of genetics-led drug discovery, Nucleome addresses the complexities of gene regulation in disease. This approach enables the development of first-in-class precision medicines by focusing on previously unexplored regulatory mechanisms. The company's technology aims to provide a deeper understanding of how genes are controlled, leading to more effective and targeted therapies.
Target Audience
The primary audience includes pharmaceutical companies and research institutions focused on developing precision medicines for complex diseases.
Features
- Advanced genomic decoding techniques for analyzing regulatory elements
- Identification of novel therapeutic targets
- Enhanced scale and precision in genetics-led drug discovery